Nanomedicines for endothelial disorders
The endothelium lines the internal surfaces of blood and lymphatic vessels and has a critical role in maintaining homeostasis. Endothelial dysfunction is involved in the pathology of many diseases and conditions, including disorders such as diabetes, cardiovascular diseases, and cancer. Given this c...
| Main Authors: | , , , , , , , , , |
|---|---|
| Other Authors: | |
| Format: | Article |
| Published: |
Elsevier
2018
|
| Online Access: | http://hdl.handle.net/1721.1/119413 https://orcid.org/0000-0002-1263-1358 https://orcid.org/0000-0002-6910-1905 https://orcid.org/0000-0001-6031-7964 https://orcid.org/0000-0003-4255-0492 |
| _version_ | 1811073528584208384 |
|---|---|
| author | Toth, Michael J. Sei, Yoshitaka J. Mulder, Willem J.M. Fayad, Zahi A. Farokhzad, Omid C. Kim, YongTae Lee Chung, Bomy Kamaly, Nazila Langer, Robert S Becraft, Jacob Robert |
| author2 | Massachusetts Institute of Technology. Department of Biological Engineering |
| author_facet | Massachusetts Institute of Technology. Department of Biological Engineering Toth, Michael J. Sei, Yoshitaka J. Mulder, Willem J.M. Fayad, Zahi A. Farokhzad, Omid C. Kim, YongTae Lee Chung, Bomy Kamaly, Nazila Langer, Robert S Becraft, Jacob Robert |
| author_sort | Toth, Michael J. |
| collection | MIT |
| description | The endothelium lines the internal surfaces of blood and lymphatic vessels and has a critical role in maintaining homeostasis. Endothelial dysfunction is involved in the pathology of many diseases and conditions, including disorders such as diabetes, cardiovascular diseases, and cancer. Given this common etiology in a range of diseases, medicines targeting an impaired endothelium can strengthen the arsenal of therapeutics. Nanomedicine - the application of nanotechnology to healthcare - presents novel opportunities and potential for the treatment of diseases associated with an impaired endothelium. This review discusses therapies currently available for the treatment of these disorders and highlights the application of nanomedicine for the therapy of these major disease complications. Keywords: Endothelium; Nanomedicine; Endothelial disorder; Diabetes; Atherosclerosis; Cancer |
| first_indexed | 2024-09-23T09:34:25Z |
| format | Article |
| id | mit-1721.1/119413 |
| institution | Massachusetts Institute of Technology |
| last_indexed | 2024-09-23T09:34:25Z |
| publishDate | 2018 |
| publisher | Elsevier |
| record_format | dspace |
| spelling | mit-1721.1/1194132022-09-26T12:20:07Z Nanomedicines for endothelial disorders Toth, Michael J. Sei, Yoshitaka J. Mulder, Willem J.M. Fayad, Zahi A. Farokhzad, Omid C. Kim, YongTae Lee Chung, Bomy Kamaly, Nazila Langer, Robert S Becraft, Jacob Robert Massachusetts Institute of Technology. Department of Biological Engineering Massachusetts Institute of Technology. Department of Chemical Engineering Koch Institute for Integrative Cancer Research at MIT Lee Chung, Bomy Kamaly, Nazila Becraft, Jacob R Langer, Robert S The endothelium lines the internal surfaces of blood and lymphatic vessels and has a critical role in maintaining homeostasis. Endothelial dysfunction is involved in the pathology of many diseases and conditions, including disorders such as diabetes, cardiovascular diseases, and cancer. Given this common etiology in a range of diseases, medicines targeting an impaired endothelium can strengthen the arsenal of therapeutics. Nanomedicine - the application of nanotechnology to healthcare - presents novel opportunities and potential for the treatment of diseases associated with an impaired endothelium. This review discusses therapies currently available for the treatment of these disorders and highlights the application of nanomedicine for the therapy of these major disease complications. Keywords: Endothelium; Nanomedicine; Endothelial disorder; Diabetes; Atherosclerosis; Cancer National Heart, Lung, and Blood Institute (Contract HHSN268201000045C) National Institutes of Health (U.S.) (Contract HHSN268201000045C) National Cancer Institute (U.S.) (Grant CA151884) 2018-12-04T17:37:53Z 2018-12-04T17:37:53Z 2016-01 2015-10 2018-12-04T14:20:05Z Article http://purl.org/eprint/type/JournalArticle 1748-0132 http://hdl.handle.net/1721.1/119413 Lee Chung, et al. “Nanomedicines for Endothelial Disorders.” Nano Today 10, 6 (December 2015): 759–776 © 2015 Elsevier Ltd https://orcid.org/0000-0002-1263-1358 https://orcid.org/0000-0002-6910-1905 https://orcid.org/0000-0001-6031-7964 https://orcid.org/0000-0003-4255-0492 http://dx.doi.org/10.1016/J.NANTOD.2015.11.009 Nano Today Creative Commons Attribution-NonCommercial-NoDerivs License http://creativecommons.org/licenses/by-nc-nd/4.0/ application/pdf Elsevier PMC |
| spellingShingle | Toth, Michael J. Sei, Yoshitaka J. Mulder, Willem J.M. Fayad, Zahi A. Farokhzad, Omid C. Kim, YongTae Lee Chung, Bomy Kamaly, Nazila Langer, Robert S Becraft, Jacob Robert Nanomedicines for endothelial disorders |
| title | Nanomedicines for endothelial disorders |
| title_full | Nanomedicines for endothelial disorders |
| title_fullStr | Nanomedicines for endothelial disorders |
| title_full_unstemmed | Nanomedicines for endothelial disorders |
| title_short | Nanomedicines for endothelial disorders |
| title_sort | nanomedicines for endothelial disorders |
| url | http://hdl.handle.net/1721.1/119413 https://orcid.org/0000-0002-1263-1358 https://orcid.org/0000-0002-6910-1905 https://orcid.org/0000-0001-6031-7964 https://orcid.org/0000-0003-4255-0492 |
| work_keys_str_mv | AT tothmichaelj nanomedicinesforendothelialdisorders AT seiyoshitakaj nanomedicinesforendothelialdisorders AT mulderwillemjm nanomedicinesforendothelialdisorders AT fayadzahia nanomedicinesforendothelialdisorders AT farokhzadomidc nanomedicinesforendothelialdisorders AT kimyongtae nanomedicinesforendothelialdisorders AT leechungbomy nanomedicinesforendothelialdisorders AT kamalynazila nanomedicinesforendothelialdisorders AT langerroberts nanomedicinesforendothelialdisorders AT becraftjacobrobert nanomedicinesforendothelialdisorders |